AR125796A1 - Compuesto cíclico que tiene una acción inhibitoria selectiva en kras sobre hras y nras - Google Patents
Compuesto cíclico que tiene una acción inhibitoria selectiva en kras sobre hras y nrasInfo
- Publication number
- AR125796A1 AR125796A1 ARP220101203A ARP220101203A AR125796A1 AR 125796 A1 AR125796 A1 AR 125796A1 AR P220101203 A ARP220101203 A AR P220101203A AR P220101203 A ARP220101203 A AR P220101203A AR 125796 A1 AR125796 A1 AR 125796A1
- Authority
- AR
- Argentina
- Prior art keywords
- kras
- hras
- nras
- cyclic compound
- inhibitory action
- Prior art date
Links
- 150000001923 cyclic compounds Chemical class 0.000 title abstract 4
- 102100029974 GTPase HRas Human genes 0.000 title 1
- 102100039788 GTPase NRas Human genes 0.000 title 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 title 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 108010038807 Oligopeptides Chemical class 0.000 abstract 3
- 102000015636 Oligopeptides Human genes 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se encontraron compuestos cíclicos y compuestos oligopeptídicos que inhiben selectivamente a KRAS. También se encontraron compuestos oligopeptídicos y aminoácidos no naturales útiles en la producción de un compuesto cíclico. Además, se descubrió que los compuestos cíclicos y los compuestos oligopeptídicos interactúan con un residuo de aminoácidos específico de KRAS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021079012 | 2021-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125796A1 true AR125796A1 (es) | 2023-08-16 |
Family
ID=83932768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101203A AR125796A1 (es) | 2021-05-07 | 2022-05-06 | Compuesto cíclico que tiene una acción inhibitoria selectiva en kras sobre hras y nras |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240158446A1 (es) |
| EP (1) | EP4309741A1 (es) |
| JP (1) | JPWO2022234853A1 (es) |
| KR (1) | KR20240005777A (es) |
| CN (1) | CN117279933A (es) |
| AR (1) | AR125796A1 (es) |
| AU (1) | AU2022268781A1 (es) |
| BR (1) | BR112023022755A2 (es) |
| CA (1) | CA3218182A1 (es) |
| CO (1) | CO2023014807A2 (es) |
| CR (1) | CR20230572A (es) |
| IL (1) | IL307605A (es) |
| MX (1) | MX2023013139A (es) |
| TW (1) | TW202309063A (es) |
| WO (1) | WO2022234853A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023214576A1 (ja) * | 2022-05-06 | 2023-11-09 | 中外製薬株式会社 | Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物 |
| WO2024085235A1 (ja) * | 2022-10-20 | 2024-04-25 | 中外製薬株式会社 | 環状ペプチドの結晶の製造方法 |
| WO2024102421A2 (en) * | 2022-11-09 | 2024-05-16 | Revolution Medicines, Inc. | Compounds, complexes, and methods for their preparation and of their use |
| WO2024101402A1 (ja) * | 2022-11-09 | 2024-05-16 | 中外製薬株式会社 | Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物を含む医薬組成物 |
| WO2024101386A1 (ja) * | 2022-11-09 | 2024-05-16 | 中外製薬株式会社 | Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物 |
| CN117486993B (zh) * | 2023-04-23 | 2024-03-26 | 山东第一医科大学(山东省医学科学院) | 订书肽及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8987412B2 (en) | 2011-03-04 | 2015-03-24 | New York University | Hydrogen bond surrogate macrocycles as modulators of Ras |
| TWI713889B (zh) | 2011-12-28 | 2020-12-21 | 中外製藥股份有限公司 | 胜肽化合物之環化方法 |
| WO2017181061A1 (en) | 2016-04-15 | 2017-10-19 | Ra Pharmaceuticals, Inc. | Ras binding peptides and methods of use |
| JP7232758B2 (ja) | 2017-06-09 | 2023-03-06 | 中外製薬株式会社 | 膜透過性の高い環状ペプチド化合物、及びこれを含むライブラリ |
| WO2018225851A1 (ja) | 2017-06-09 | 2018-12-13 | 中外製薬株式会社 | Ｎ－置換アミノ酸を含むペプチドの合成方法 |
| KR20210102326A (ko) * | 2018-12-12 | 2021-08-19 | 추가이 세이야쿠 가부시키가이샤 | 분자내 수소 결합 가능한 작용기를 갖는 아미노산과 그들 아미노산을 포함하는 펩타이드 화합물, 및 그들의 제조 방법 |
| PE20221323A1 (es) * | 2019-11-07 | 2022-09-09 | Chugai Pharmaceutical Co Ltd | Compuesto de peptidos ciclicos que tiene accion inhibidora de kras |
-
2022
- 2022-05-06 AU AU2022268781A patent/AU2022268781A1/en active Pending
- 2022-05-06 WO PCT/JP2022/019544 patent/WO2022234853A1/ja active Application Filing
- 2022-05-06 IL IL307605A patent/IL307605A/en unknown
- 2022-05-06 BR BR112023022755A patent/BR112023022755A2/pt unknown
- 2022-05-06 CR CR20230572A patent/CR20230572A/es unknown
- 2022-05-06 KR KR1020237040757A patent/KR20240005777A/ko unknown
- 2022-05-06 JP JP2023518700A patent/JPWO2022234853A1/ja active Pending
- 2022-05-06 CA CA3218182A patent/CA3218182A1/en active Pending
- 2022-05-06 US US18/289,592 patent/US20240158446A1/en active Pending
- 2022-05-06 MX MX2023013139A patent/MX2023013139A/es unknown
- 2022-05-06 EP EP22798957.1A patent/EP4309741A1/en active Pending
- 2022-05-06 TW TW111117092A patent/TW202309063A/zh unknown
- 2022-05-06 CN CN202280032929.5A patent/CN117279933A/zh active Pending
- 2022-05-06 AR ARP220101203A patent/AR125796A1/es unknown
-
2023
- 2023-10-31 CO CONC2023/0014807A patent/CO2023014807A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117279933A (zh) | 2023-12-22 |
| JPWO2022234853A1 (es) | 2022-11-10 |
| BR112023022755A2 (pt) | 2024-01-02 |
| CO2023014807A2 (es) | 2023-11-20 |
| EP4309741A1 (en) | 2024-01-24 |
| WO2022234853A1 (ja) | 2022-11-10 |
| MX2023013139A (es) | 2023-11-28 |
| CR20230572A (es) | 2024-01-25 |
| CA3218182A1 (en) | 2022-11-10 |
| AU2022268781A1 (en) | 2023-12-21 |
| IL307605A (en) | 2023-12-01 |
| KR20240005777A (ko) | 2024-01-12 |
| TW202309063A (zh) | 2023-03-01 |
| US20240158446A1 (en) | 2024-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR125796A1 (es) | Compuesto cíclico que tiene una acción inhibitoria selectiva en kras sobre hras y nras | |
| AR117101A1 (es) | Síntesis mejorada del intermedio clave del compuesto inhibidor de g12c de kras | |
| AR120394A1 (es) | Compuesto de péptido cíclico que tiene acción inhibitoria de kras | |
| CO2022010098A2 (es) | Inhibidores de proteínas kras mutantes | |
| PE20221339A1 (es) | Inhibidores de parp1 | |
| UY39526A (es) | Inhibidores de kras g12d | |
| DE602004018615D1 (de) | Heterosubstituierte natriumkanalblocker | |
| CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
| ECSP088258A (es) | Inhibidores de serina proteasas | |
| RS52632B (en) | S-TRIAZOLYL ALFA-MERCAPTOACETANILIDE AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | |
| ECSP066992A (es) | ÁCIDO 2-{[2-(2-METILAMINOPIRIMIDIN-4-IL)-1H-INDOL-5-CARBONIL]AMINO}-3-(FENILPIRIDIN-2-ILAMINO)PROPIÓNICOSUSTANCIALMENTE PURO COMO INHIBIDOR DE LA CINASA IkB | |
| AR074627A1 (es) | Resinas de melamina urea formaldehido estables durante el almacenamiento y aplicaciones de las mismas | |
| CR9145A (es) | Procedimiento para intensificar la eficiencia de etaboxam | |
| AR031520A1 (es) | Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion | |
| ECSP093680A (es) | Proceso para derivados del acido fenilacetico | |
| CO2021008816A2 (es) | Moduladores de trex1 | |
| CO2022003608A2 (es) | Cianopirrolidinas sustituidas con actividad como inhibidores de usp30 | |
| ES2180933T3 (es) | Inhibidor de la serina-proteasa. | |
| ATE382604T1 (de) | Aminosäure-derivate als hiv aspartyl-protease- inhibitoren | |
| CL2022000725A1 (es) | Inhibidor de irak y método de preparación para el mismo y uso del mismo | |
| AR093738A1 (es) | Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos | |
| AR091888A1 (es) | Compuestos de urea y su uso como inhibidores de enzimas | |
| PE20220591A1 (es) | Composicion farmaceutica que contiene acetaminofeno e ibuprofeno | |
| ES2155091T3 (es) | Procedimiento para la produccion de inhibidores de la proteasa del vih. | |
| AR128066A1 (es) | Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos |